Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Last searches

Results for *

Displaying results 1 to 4 of 4.

  1. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide–Based Vaccine in Patients With Refractory Advanced Non–Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study ; Quelle formation académique pour les nouvelles missions de pharmacie clinique à l’officine ? Exemple du bilan partagé de médication du sujet âgé
    Author: Adotévi, Olivier; Vernerey, Dewi; Jacoulet, Pascale; Meurisse, Aurélia; Laheurte, Caroline; Almotlak, Hamadi; Jacquin, Marion; Kaulek, Vincent; Boullerot, Laura; Malfroy, Marine; Orillard, Emeline; Eberst, Guillaume; Lagrange, Aurélie; Favier, Laure; Gainet-Brun, Marie; Doucet, Ludovic; Teixeira, Luis; Ghrieb, Zineb; Clairet, Anne-Laure; Guillaume, Yves; Kroemer, Marie; Hocquet, Didier; Moltenis, Mélanie; Limat, Samuel; Quoix, Elisabeth; Mascaux, Céline; Debieuvre, Didier; Fagnoni-Legat, Christine; Borg, Christophe; Westeel, Virginie
    Published: 2023
    Publisher:  HAL CCSD ; American Society of Clinical Oncology

    PURPOSE Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase. This phase Ib/IIa trial was designed to test the safety,... more

     

    PURPOSE Universal cancer peptide–based vaccine (UCPVax) is a therapeutic vaccine composed of two highly selected helper peptides to induce CD4+ T helper-1 response directed against telomerase. This phase Ib/IIa trial was designed to test the safety, immunogenicity, and efficacy of a three-dose schedule in patients with metastatic non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS Patients with refractory NSCLC were assigned to receive three vaccination doses of UCPVax (0.25 mg, 0.5 mg, and 1 mg) using a Bayesian-based phase Ib followed by phase IIa de-escalating design. The primary end points were dose-limiting toxicity and immune response after three first doses of vaccine. Secondary end points were overall survival (OS) and progression-free survival at 1 year. RESULTS A total of 59 patients received UCPVax; 95% had three prior lines of systemic therapy. No dose-limiting toxicity was observed in 15 patients treated in phase Ib. The maximum tolerated dose was 1 mg. Fifty-one patients were eligible for phase IIa. The third and sixth dose of UCPVax induced specific CD4+ T helper 1 response in 56% and 87.2% of patients, respectively, with no difference between three dose levels. Twenty-one (39%) patients achieved disease control (stable disease, n = 20; complete response, n = 1). The 1-year OS was 34.1% (95% CI, 23.1 to 50.4), and the median OS was 9.7 months, with no significant difference between dose levels. The 1-year progression-free survival and the median OS were 17.2% (95% CI, 7.8 to 38.3) and 11.6 months (95% CI, 9.7 to 16.7) in immune responders ( P = .015) and 4.5% (95% CI, 0.7 to 30.8) and 5.6 months (95% CI, 2.5 to 10) in nonresponders ( P = .005), respectively. CONCLUSION UCPVax was highly immunogenic and safe and provide interesting 1-year OS rate in heavily pretreated advanced NSCLC.

     
    Export to reference management software   RIS file
      BibTeX file
    Source: BASE Selection for Comparative Literature
    Language: English
    Media type: Article (journal)
    Format: Online
    Parent title: ISSN: 0732-183X ; EISSN: 1527-7755 ; Journal of Clinical Oncology ; https://hal.science/hal-04157792 ; Journal of Clinical Oncology, 2023, 41 (2), pp.373-384. ⟨10.1200/JCO.22.00096⟩
    Subjects: Age; Carriage; Individual acquisition; Polyclonal population structure; Pseudomonas aeruginosa; Aged; Clinical pharmacy; Enseignement supérieur; Graduate education; Pharmacie clinique; Pharmacy students; Sujet âgé; Étudiants en pharmacie; MESH: Humans; MESH: Bayes Theorem; MESH: Cancer Vaccines; MESH: Carcinoma; Non-Small-Cell Lung; MESH: Lung Neoplasms; MESH: Vaccines; Subunit; MESH: Immunogenicity; Vaccine; [SDV]Life Sciences [q-bio]
  2. Vaccination under the pandemic and political support
    Author: Takahashi, Masaki; Takaku, Reo; Ashida, Toyo; Ibuka, Yōko
    Published: 15 February, 2022
    Publisher:  Institute for Economic Studies, Keio University, Tokyo, Japan

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    VS 627
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: KEIO-IES discussion paper series ; DP2022, 003 (15 February, 2022)
    Subjects: COVID-19; Vaccine; Political Support; Regression Discontinuity Design; Reciprocity
    Scope: 1 Online-Ressource (circa 54 Seiten), Illustrationen
  3. Parental decision and intent towards COVID-19 vaccination in children with Asthma
    an econometric analysis
    Author: Drouin, Olivier; Montmarquette, Claude; Prud’homme, Alexandre; Arnaud, Yann; Fontaine, Pierre; Borgès Da Silva, Roxane
    Published: [2021]
    Publisher:  CIRANO, [Montréal]

    Access:
    Verlag (kostenfrei)
    Verlag (kostenfrei)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: Cahier scientifique / CIRANO ; 2021s, 08
    Subjects: COVID-19; Vaccine; Asthmatic Children; Parental Decisions; Econometric Modeling
    Scope: 1 Online-Ressource (circa 21 Seiten), Illustrationen
  4. Could vaccine dose stretching reduce COVID-19 deaths?
    Author: Więcek, Witold; Ahuja, Amrita; Kremer, Michael; Simoes Gomes, Alexandre; Snyder, Christopher M.; Tabarrok, Alexander; Tan, Brandon Joel
    Published: 03 July 2021
    Publisher:  Centre for Economic Policy Research, London

    Access:
    Verlag (lizenzpflichtig)

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    LZ 161
    Inter-library loan:
    No inter-library loan

    Location:
    Universitätsbibliothek Mannheim
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: Array ; DP16324
    Subjects: Vaccine; Pandemic; epidemiology; Public health; Supply Chains
    Scope: 1 Online-Ressource (circa 71 Seiten), Illustrationen